Andrew Nash

Dr. Andrew Nash is the Chief Scientific Officer and Senior Vice President, Research at CSL Limited. After a PhD (1988) and academic career at The University of Melbourne, in 1996 he joined the ASX listed biotechnology company Zenyth Therapeutics as a senior scientist and subsequently held several positions including Director of Biologicals Research and Chief Scientific Officer. In July of 2005 he was appointed Chief Executive Officer of Zenyth, a position which he held up until the acquisition of Zenyth by CSL Limited in November 2006. Following the acquisition, he was appointed as CSL’s SVP, Research and is currently based at the Bio21 Institute where he leads a large global effort focused on the discovery and development of new protein, cell, and gene-based medicines. He was appointed as CSL’s Chief Scientific Officer in 2020.